Product Image

Contributor Information

  • Name Roy Jefferis
  • Institute University of Birmingham

Tool Details

  • Tool name: Anti-CD19 [BU12]
  • Alternate names: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
  • Clone: BU12
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IP
  • Strain: Balb/c
  • Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
  • Immunogen: Human EB-4 Burkitt's lymphoma cell line
  • Isotype: IgG1
  • Research area: Cancer; Cell signaling and signal transduction; Immunology; Stem cell biology

  • For Research Use Only

Target Details

  • Target: CD19
  • Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Application Details

  • Application: FACS ; IHC ; IP

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-porcine thermal-stable blood protein (TSBP) (90 kDa) [19C5E10]

#156458
Product Image

Anti-gp91phox [CL5]

#154135
Product Image

Anti-splitGFP S11 [7G8-D6]

#161718

References

  • •  Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
  • •  High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
  • •  Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
  • •  The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
  • •  Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
  • •  Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.
  • •  Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
  • •  Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
  • •  CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.